Vaxart, Inc. Form 4 (June 16, 2021) — Tucker Sean

Summary

Sean N. Tucker, SVP, Chief Scientific Officer of Vaxart, Inc., reports on this Form 4 the acquisition on 06/16/2021 of a stock option (right to buy) for 100,000 shares of common stock with a $6.27 exercise price and an expiration date of 03/24/2031. The board of directors approved the grant on March 25, 2021, subject to stockholder approval of a plan amendment to the Vaxart, Inc. 2019 Equity Incentive Plan, and the stockholders approved it on June 16, 2021, the footnotes state. A quarter of the shares (25%) vest on March 25, 2022, with the rest in 36 equal monthly installments through March 25, 2025. Sean N. Tucker signed on 06/17/2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * Tucker Sean (Last) (First) (Middle) C/O VAXART, INC. 170 HARBOR WAY, SUITE 300 (Street) SOUTH SAN FRANCISCO CA 94080 (City) (State) (Zip) | Tucker Sean | (Last) | (First) | (Middle) | C/O VAXART, INC. | 170 HARBOR WAY, SUITE 300 | SOUTH SAN FRANCISCO | CA | 94080 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Vaxart, Inc. [ VXRT ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) SVP, Chief Scientific Officer | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | SVP, Chief Scientific Officer
3. Date of Earliest Transaction
 (Month/Day/Year) 06/16/2021
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Stock Option (right to buy) | $ 6.27 | 06/16/2021 (1) | A | 100,000 | (2) | 03/24/2031 | Common stock | 100,000 | $ 0 | 100,000 | D
Explanation of Responses:
1. The option grant was approved by the board of directors of Vaxart, Inc. on March 25, 2021, subject to stockholder approval of an amendment to the Vaxart, Inc. 2019 Equity Incentive Plan, under which the stock option was granted. Vaxart, Inc.'s stockholders approved the plan amendment on June 16, 2021.
2. The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 25, 2022, the first anniversary of the date that the grant was approved by the board of directors, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 25, 2025.
/s/ Sean N. Tucker | 06/17/2021
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_VXRT_4_filed2021-06-17_0001437749-21-015074.xml

Size

15,929 bytes

SHA-256

3b5ed04a51042e0ce0d93875b16ca047e5cfc8136114eec896c052445d90a6cb

Our copy

SEC_VXRT_4_filed2021-06-17_0001437749-21-015074.xml

Original

www.sec.gov